Published in Nature on August 18, 2013
Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science (2013) 3.90
AIRE-Deficient Patients Harbor Unique High-Affinity Disease-Ameliorating Autoantibodies. Cell (2016) 2.19
Rapid development of broadly influenza neutralizing antibodies through redundant mutations. Nature (2014) 1.65
Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies. Front Immunol (2014) 1.28
Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein. PLoS Pathog (2015) 1.23
Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med (2015) 1.17
A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat Commun (2015) 1.12
Fusion activation through attachment protein stalk domains indicates a conserved core mechanism of paramyxovirus entry into cells. J Virol (2014) 1.04
Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection. Cell (2016) 1.02
Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies. Proc Natl Acad Sci U S A (2014) 0.99
An overview of respiratory syncytial virus. PLoS Pathog (2014) 0.99
Novel antigens for RSV vaccines. Curr Opin Immunol (2015) 0.99
A broadly neutralizing human monoclonal antibody exhibits in vivo efficacy against both human metapneumovirus and respiratory syncytial virus. J Infect Dis (2014) 0.96
Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein. Curr Opin Virol (2015) 0.90
Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis. Nat Commun (2015) 0.90
Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. J Exp Med (2016) 0.87
Probing the paramyxovirus fusion (F) protein-refolding event from pre- to postfusion by oxidative footprinting. Proc Natl Acad Sci U S A (2014) 0.87
Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. Nat Struct Mol Biol (2016) 0.85
A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus. PLoS One (2015) 0.85
Determinants of early life immune responses to RSV infection. Curr Opin Virol (2016) 0.81
Antigenic Fingerprinting following Primary RSV Infection in Young Children Identifies Novel Antigenic Sites and Reveals Unlinked Evolution of Human Antibody Repertoires to Fusion and Attachment Glycoproteins. PLoS Pathog (2016) 0.81
Vaccines against respiratory syncytial virus: The time has finally come. Vaccine (2016) 0.81
Applying contemporary immunology to elucidate heterologous effects of infant vaccines and to better inform maternal-infant immunization practices. Front Immunol (2015) 0.81
Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus. PLoS One (2016) 0.81
SnapShot: broadly neutralizing antibodies. Cell (2013) 0.80
A Chimeric Pneumovirus Fusion Protein Carrying Neutralizing Epitopes of Both MPV and RSV. PLoS One (2016) 0.79
Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses. J Virol (2016) 0.79
New Approaches for Immunization and Therapy against Human Metapneumovirus. Clin Vaccine Immunol (2015) 0.79
Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci Immunol (2016) 0.78
A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation. Nat Commun (2016) 0.77
Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV. J Virol (2016) 0.77
Engineering, Structure and Immunogenicity of the Human Metapneumovirus F Protein in the Postfusion Conformation. PLoS Pathog (2016) 0.77
A novel antibody discovery platform identifies anti-influenza A broadly neutralizing antibodies from human memory B cells. MAbs (2016) 0.77
Discovery and Characterization of Phage Display-Derived Human Monoclonal Antibodies against RSV F Glycoprotein. PLoS One (2016) 0.77
Respiratory Syncytial Virus (RSV) Pulmonary Infection in Humanized Mice Induces Human Anti-RSV Immune Responses and Pathology. J Virol (2016) 0.77
Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primates. Vaccine (2016) 0.76
Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein. Clin Vaccine Immunol (2016) 0.76
Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus. Nat Microbiol (2017) 0.75
Analysis of Human RSV Immunity at the Molecular Level: Learning from the Past and Present. PLoS One (2015) 0.75
Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein. PLoS One (2016) 0.75
Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection. Vaccine (2016) 0.75
Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development. Vaccine (2016) 0.75
Immobilization of the N-terminal helix stabilizes prefusion paramyxovirus fusion proteins. Proc Natl Acad Sci U S A (2016) 0.75
Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B. PLoS One (2017) 0.75
Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state. Nat Commun (2017) 0.75
Human metapneumovirus in the preterm neonate: current perspectives. Res Rep Neonatol (2016) 0.75
TRIVALENCY OF A NANOBODY SPECIFIC FOR THE HUMAN RESPIRATORY SYNCYTIAL VIRUS FUSION GLYCOPROTEIN DRASTICALLY ENHANCES VIRUS NEUTRALIZATION AND IMPACTS ON ESCAPE MUTANT SELECTION. Antimicrob Agents Chemother (2016) 0.75
Serology Enhances Molecular Diagnosis of Respiratory Virus Infections Other than Influenza in Children and Adults Hospitalized with Community-Acquired Pneumonia. J Clin Microbiol (2016) 0.75
Antibody-induced internalization of the human respiratory syncytial virus fusion protein. J Virol (2017) 0.75
Broadly Reactive Anti-Respiratory Syncytial Virus G Antibodies from Exposed Individuals Effectively Inhibit Infection of Primary Airway Epithelial Cells. J Virol (2017) 0.75
In silico analysis of amino acid variation in human respiratory syncytial virus: insights into immunodiagnostics. Mem Inst Oswaldo Cruz (2017) 0.75
What Are the Most Powerful Immunogen Design Vaccine Strategies? Reverse Vaccinology 2.0 Shows Great Promise. Cold Spring Harb Perspect Biol (2017) 0.75
Protection of calves by a prefusion-stabilized bovine RSV F vaccine. NPJ Vaccines (2017) 0.75
A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein. Nat Microbiol (2017) 0.75
MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol (2011) 220.97
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics (1998) 49.00
A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med (2001) 16.32
Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med (2005) 9.47
The burden of respiratory syncytial virus infection in young children. N Engl J Med (2009) 8.95
Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med (2004) 7.71
Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods (2007) 5.97
IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res (2008) 5.42
An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med (2004) 4.89
Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science (2013) 2.95
Human metapneumovirus in severe respiratory syncytial virus bronchiolitis. Emerg Infect Dis (2003) 2.78
Broadly neutralizing antiviral antibodies. Annu Rev Immunol (2013) 2.77
Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol (1989) 2.59
Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A (2011) 2.08
Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat Med (2009) 2.03
Refolding of a paramyxovirus F protein from prefusion to postfusion conformations observed by liposome binding and electron microscopy. Proc Natl Acad Sci U S A (2006) 2.03
The role of IFN in respiratory syncytial virus pathogenesis. J Immunol (2002) 1.95
Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies. Virology (2000) 1.87
Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci U S A (2012) 1.80
Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood (2010) 1.77
Burden of human metapneumovirus infection in young children. N Engl J Med (2013) 1.65
Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F. J Virol (2010) 1.38
Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Res (2003) 1.29
Functional antagonism of chemokine receptor CCR1 reduces mortality in acute pneumovirus infection in vivo. J Virol (2004) 1.28
Functional reconstruction and synthetic mimicry of a conformational epitope using CLIPS technology. J Mol Recognit (2007) 1.21
Structural aspects of antibody-antigen interaction revealed through small random peptide libraries. Mol Divers (1996) 1.20
Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group. Pediatrics (1995) 1.19
The microbiology of asthma. Nat Rev Microbiol (2012) 1.14
Animal models for studying respiratory syncytial virus infection and its long term effects on lung function. Pediatr Infect Dis J (2004) 1.11
Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo. J Virol (2006) 1.09
Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. Clin Infect Dis (2007) 1.05
Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats. Virology (2004) 1.05
Palivizumab-resistant human respiratory syncytial virus infection in infancy. Clin Infect Dis (2010) 1.04
Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility to palivizumab. J Infect Dis (2011) 0.99
Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol (2004) 17.54
Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol (2007) 13.70
Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol (2007) 12.72
Maintenance of serological memory by polyclonal activation of human memory B cells. Science (2002) 8.75
A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science (2011) 7.86
Development of a human adaptive immune system in cord blood cell-transplanted mice. Science (2004) 7.07
Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol (2005) 6.81
C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol (2009) 5.97
Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol (2004) 5.80
Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One (2010) 5.73
An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med (2004) 4.89
Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A (2008) 4.71
Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol (2009) 4.69
Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med (2003) 4.64
Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest (2010) 4.62
Progressive differentiation and selection of the fittest in the immune response. Nat Rev Immunol (2002) 4.17
IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science (2009) 3.90
Follicular B helper T cell activity is confined to CXCR5(hi)ICOS(hi) CD4 T cells and is independent of CD57 expression. Eur J Immunol (2006) 3.85
Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β. Nature (2012) 3.85
A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood (2003) 3.77
T cell fitness determined by signal strength. Nat Immunol (2003) 3.65
Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med (2007) 3.63
The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. J Immunol (2002) 3.48
The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe (2010) 3.48
Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol (2004) 3.42
From vaccines to memory and back. Immunity (2010) 3.30
Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J Exp Med (2005) 3.29
Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood (2003) 3.23
Understanding the generation and function of memory T cell subsets. Curr Opin Immunol (2005) 3.22
Memory and flexibility of cytokine gene expression as separable properties of human T(H)1 and T(H)2 lymphocytes. Nat Immunol (2002) 3.07
T cell costimulation by chemokine receptors. Nat Immunol (2005) 3.00
Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol (2006) 2.94
Broadly neutralizing antiviral antibodies. Annu Rev Immunol (2013) 2.77
Coronaviruses Hijack the LC3-I-positive EDEMosomes, ER-derived vesicles exporting short-lived ERAD regulators, for replication. Cell Host Microbe (2010) 2.75
CXCR5 expressing human central memory CD4 T cells and their relevance for humoral immune responses. J Immunol (2011) 2.54
L-selectin-negative CCR7- effector and memory CD8+ T cells enter reactive lymph nodes and kill dendritic cells. Nat Immunol (2007) 2.51
Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Med (2009) 2.47
Dysregulation of allergic airway inflammation in the absence of microbial colonization. Am J Respir Crit Care Med (2011) 2.45
Chemokine receptor expression identifies Pre-T helper (Th)1, Pre-Th2, and nonpolarized cells among human CD4+ central memory T cells. J Exp Med (2004) 2.38
IL-36R ligands are potent regulators of dendritic and T cells. Blood (2011) 2.20
Persistent antigen and germinal center B cells sustain T follicular helper cell responses and phenotype. Immunity (2013) 2.13
TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses. J Immunol (2007) 2.11
Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog (2012) 2.02
Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells. Blood (2012) 2.00
Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol (2009) 1.92
In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis (2011) 1.92
Heterogeneity of CD4+ memory T cells: functional modules for tailored immunity. Eur J Immunol (2009) 1.92
Pivotal role of dendritic cell-derived CXCL10 in the retention of T helper cell 1 lymphocytes in secondary lymph nodes. J Exp Med (2002) 1.91
Of flies, mice and men: a systematic approach to understanding the early life origins of chronic lung disease. Thorax (2012) 1.88
Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8+ T cells. J Gen Virol (2005) 1.83
Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur J Immunol (2002) 1.80
IL-21 receptor signaling is integral to the development of Th2 effector responses in vivo. Blood (2006) 1.79
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A (2007) 1.76
Activation of the Flt3 signal transduction cascade rescues and enhances type I interferon-producing and dendritic cell development. J Exp Med (2006) 1.75
Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc Natl Acad Sci U S A (2005) 1.75
Clonal dissection of the human memory B-cell repertoire following infection and vaccination. Eur J Immunol (2009) 1.74
Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness. J Exp Med (2010) 1.74
Postinfectious neurologic syndromes: a prospective cohort study. Neurology (2013) 1.73
Identification of T cell-restricted genes, and signatures for different T cell responses, using a comprehensive collection of microarray datasets. J Immunol (2005) 1.73
pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO J (2008) 1.72
Human naive and memory CD4+ T cell repertoires specific for naturally processed antigens analyzed using libraries of amplified T cells. J Exp Med (2009) 1.71